CAY10704 is a potent inhibitor of hepatitis C virus (HCV) infection (EC₅₀ = 17 nM) that displays low cytotoxicity of virally-infected human hepatoma Huh7.5.1 cells (CC₅₀ = 21.3 µM).¹ It displays good pharmacokinetics in mice when delivered intraperitoneally, with preferential liver distribution without significant hepatotoxicity.¹ CAY10704 is selective for HCV over dengue virus (EC₅₀ = 4.62 µM).¹

≥98%

Store at -20℃

1.He, S.,Xiao, J.,Dulcey, A.E., et al. Discovery, optimization, and characterization of novel chlorcyclizine derivatives for the treatment of hepatitis C virus infection. Journal of Medicinal Chemistry 59(3), 841-853 (2016).